Clinical trial
Gemcitabine for Marginal Zone Lymphoma
NCT00337259 · Asan Medical Center, Other · Terminated
Key facts
| NCT number | NCT00337259 |
|---|---|
| Title | Gemcitabine for Marginal Zone Lymphoma |
| Official title | Phase II Study of Gemcitabine in Patients With Advanced Stage Marginal Zone B-cell Lymphoma |
| Lead sponsor | Asan Medical Center, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma, Marginal Zone Lymphoma |
| Intervention type | Drug |
| Interventions | gemcitabine |
| Enrollment | 43 |
| Start date | Jun 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Jun 15, 2006 |
| Last update posted | Feb 17, 2016 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: